These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31006923)

  • 1. Cost-effectiveness of five prenatal screening strategies for trisomies and other unbalanced chromosomal abnormalities: model-based analysis.
    Le Bras A; Salomon LJ; Bussières L; Malan V; Elie C; Mahallati H; Ville Y; Vekemans M; Durand-Zaleski I
    Ultrasound Obstet Gynecol; 2019 Nov; 54(5):596-603. PubMed ID: 31006923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
    Galeva S; Konstantinidou L; Gil MM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Feb; 53(2):208-213. PubMed ID: 30353581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
    Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIDENT-2: National Implementation of Genome-wide Non-invasive Prenatal Testing as a First-Tier Screening Test in the Netherlands.
    van der Meij KRM; Sistermans EA; Macville MVE; Stevens SJC; Bax CJ; Bekker MN; Bilardo CM; Boon EMJ; Boter M; Diderich KEM; de Die-Smulders CEM; Duin LK; Faas BHW; Feenstra I; Haak MC; Hoffer MJV; den Hollander NS; Hollink IHIM; Jehee FS; Knapen MFCM; Kooper AJA; van Langen IM; Lichtenbelt KD; Linskens IH; van Maarle MC; Oepkes D; Pieters MJ; Schuring-Blom GH; Sikkel E; Sikkema-Raddatz B; Smeets DFCM; Srebniak MI; Suijkerbuijk RF; Tan-Sindhunata GM; van der Ven AJEM; van Zelderen-Bhola SL; Henneman L; Galjaard RH; Van Opstal D; Weiss MM;
    Am J Hum Genet; 2019 Dec; 105(6):1091-1101. PubMed ID: 31708118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot study.
    Sánchez-Durán MÁ; Bernabeu García A; Calero I; Ramis Fossas J; Illescas T; Avilés MT; Maiz N; Carreras E
    BMC Pregnancy Childbirth; 2019 Aug; 19(1):274. PubMed ID: 31370808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test.
    Gil MM; Revello R; Poon LC; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jan; 47(1):45-52. PubMed ID: 26498918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13.
    Bestwick JP; Wald NJ
    PLoS One; 2019; 14(7):e0220053. PubMed ID: 31344071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy.
    Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):318-324. PubMed ID: 28833712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2019; 19(4):1-166. PubMed ID: 30847010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysis.
    Prefumo F; Paolini D; Speranza G; Palmisano M; Dionisi M; Camurri L
    PLoS One; 2019; 14(6):e0218166. PubMed ID: 31188879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of cell-free DNA testing for common fetal trisomies in triplet pregnancies.
    Zakaria H; Kleinfinger P; Lohmann L; Costa JM; Tsatsaris V; Salomon LJ; Jouannic JM; Rosenblatt J; Demain A; Benachi A; El Khattabi L; Vivanti AJ
    Prenat Diagn; 2024 May; 44(5):555-561. PubMed ID: 38448008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result.
    Revello R; Sarno L; Ispas A; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jun; 47(6):698-704. PubMed ID: 26743020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free DNA screening for aneuploidies in 7113 pregnancies: single Italian centre study.
    Mesoraca A; Margiotti K; Dello Russo C; Cesta A; Cima A; Longo SA; Barone MA; Viola A; Sparacino D; Giorlandino C
    Genet Res (Camb); 2020 Jun; 102():e5. PubMed ID: 32539871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State-wide utilization and performance of traditional and cell-free DNA-based prenatal testing pathways: the Victorian Perinatal Record Linkage (PeRL) study.
    Lindquist A; Hui L; Poulton A; Kluckow E; Hutchinson B; Pertile MD; Bonacquisto L; Gugasyan L; Kulkarni A; Harraway J; Howden A; McCoy R; Da Silva Costa F; Menezes M; Palma-Dias R; Nisbet D; Martin N; Bethune M; Poulakis Z; Halliday J
    Ultrasound Obstet Gynecol; 2020 Aug; 56(2):215-224. PubMed ID: 31625225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness analysis comparing two different strategies in advanced maternal age: Combined first-trimester screening and maternal blood cell-free DNA testing.
    Pan M; Huang LY; Zhen L; Li DZ
    Taiwan J Obstet Gynecol; 2018 Aug; 57(4):536-540. PubMed ID: 30122574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory.
    Petersen AK; Cheung SW; Smith JL; Bi W; Ward PA; Peacock S; Braxton A; Van Den Veyver IB; Breman AM
    Am J Obstet Gynecol; 2017 Dec; 217(6):691.e1-691.e6. PubMed ID: 29032050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice.
    Salomon LJ; Alfirevic Z; Audibert F; Kagan KO; Paladini D; Yeo G; Raine-Fenning N;
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):815-816. PubMed ID: 28573775
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Validation of Non-Invasive Prenatal Testing for Fetal Common Aneuploidies in 1,055 Korean Pregnant Women: a Single Center Experience.
    Lee DE; Kim H; Park J; Yun T; Park DY; Kim M; Ryu HM
    J Korean Med Sci; 2019 Jun; 34(24):e172. PubMed ID: 31222985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review.
    García-Pérez L; Linertová R; Álvarez-de-la-Rosa M; Bayón JC; Imaz-Iglesia I; Ferrer-Rodríguez J; Serrano-Aguilar P
    Eur J Health Econ; 2018 Sep; 19(7):979-991. PubMed ID: 29249015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis.
    Gil MM; Galeva S; Jani J; Konstantinidou L; Akolekar R; Plana MN; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Jun; 53(6):734-742. PubMed ID: 31165549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.